1-4 of 4
Chiaki Tanaka
Close
Sort by
Journal Articles

Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients with Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results from the Phase II, Multicenter, Open-Label Solace-Adults Study

Darla Liles, MD, Kim Smith-Whitley, MD, R Clark Brown, MD PhD, Nirmish Shah, MD, Santosh M Nair, MD, Chiaki Tanaka, PhD, Shankaranand Bodla, Gessami Sanchez-Olle, PhD, Urs Albers, PhD, Julie Kanter, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–19.
https://doi.org/10.1182/blood-2020-137434
Published: 2020
Journal Articles

Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease

Julie Kanter, MD, Brian Elliott, Denis Weber, Chiaki Tanaka, Fang Xiang, Kenneth I Ataga, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4782.
https://doi.org/10.1182/blood.V130.Suppl_1.4782.4782
Published: 2017
Journal Articles

Pharmacokinetics of Nilotinib in Subjects with Normal or Impaired Hepatic Function.

Jaymes Holland, RPh, Chiaki Tanaka, PhD, Wei Zhou, PhD, Venkat Sethuraman, MS, Douglas M. Heuman, MD, Horst Schran
Journal: Blood
Blood (2007) 110 (11): 2379.
https://doi.org/10.1182/blood.V110.11.2379.2379
Published: 2007
Journal Articles

Safety, Pharmacokinetics (PK), Metabolism, and Mass Balance of [ 14 C]-AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl Tyrosine Kinase, in Healthy Subjects.

Mark Kagan, PhD, Phi Tran, M.Sc, Volker Fischer, PhD, Paula Savage, MS, Tom Smith, BS, Chiaki Tanaka, PhD, Horst Schran, PhD, Milind Narurkar, PhD, PharmD, Leila Alland, MD
Journal: Blood
Blood (2005) 106 (11): 4887.
https://doi.org/10.1182/blood.V106.11.4887.4887
Published: 2005